German G-BA to get new panel under health reform
This article was originally published in Clinica
The German healthcare financing draft bill, currently in parliamentary debate ahead of a planned April 2007 enforcement, will have a significant fall out on the Gemeinsamer Bundesausschuss (joint federal committee), the body that rules on the introduction of reimbursable medical products and procedures. In the future, the G-BA will also include independent, full-time members, who are to be appointed by the self-governing bodies (the German hospital federation - DKG; doctors; and health insurance fund associations), according to MedInsight*, the monthly newsletter from BVMed/MedInform.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.